A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.
Tocilizumab treatment results in a “rapid and maintained” clinical improvement among patients with giant cell arteritis in routine clinical practice, researchers report.
Findings from a randomized trial suggest that treatment with the interleukin-1 receptor antagonist anakinra is noninferior to usual care for the treatment of gout flares.
Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.
Mycophenolate mofetil is noninferior to cyclophosphamide for inducing remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, randomized trial data show.
Source:
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-214245
Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.
Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.
Findings from two registry studies of patients with rheumatoid arthritis suggest that serious infection risk may differ by the type of biological agent used.
Source:
Arthritis Care Res 2018; doi:10.1002/acr.23824 Ann Rheum Dis 2019; doi:10.1136/annrheumdis-2018-214326
Implementation of a bundled-payment program has led to a “modest reduction” in spending on knee and hip replacement operations in the USA, say researchers.
Findings from an observational study suggest that methotrexate treatment, with a dose-escalation strategy targeting remission, improves the joint and skin manifestations of psoriatic arthritis.
Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.
Findings from a systematic review and network meta-analysis published in JAMA indicate that it is not clear whether pharmacologic treatments offer long-term benefits for patients with knee osteoarthritis.
Levels of serum calprotectin are significantly associated with the risk of disease relapse among tumour necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis, researchers report.
Findings from a randomized trial indicate that treatment with the interleukin-1α and -1β inhibitor lutikizumab does not improve pain or imaging outcomes among patients with erosive hand osteoarthritis.
Source:
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213336
Treatment with abatacept is associated with improvements in patient-reported outcomes among individuals with psoriatic arthritis, study findings suggest.
Adding abatacept to methotrexate improves disease activity and reduces structural progression among ACPA-positive rheumatoid arthritis patients with early erosion, Japanese researchers report.
Patients with large vessel involvement when diagnosed with biopsy-confirmed giant cell arteritis have a substantially increased risk of death relative to patients with no large vessel involvement, Italian researchers report.
Results of an observational study provide preliminary evidence suggesting that patients with gout and fatty liver disease who are treated with febuxostat do not have an elevated risk for hepatotoxicity.
The American College of Rheumatology and the National Psoriasis Foundation have issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis.
Source:
Arthritis Rheumatol 2018; doi:10.1002/art.40726 Arthritis Care Res 2018; doi:10.1002/acr.23789 J Psoriasis Psoriatic Arthritis 2018; doi:10.1177/2475530318812244